The modern approach of treatment of community acquired pneumonia in hospitalized patients. Focus on efficiency and safety

Abstract

This article is to show new facts on the sensitivity of antibiotics (APM) to major pathogens of community acquired pneumonia obtained upon studying the resistance in Ukraine. Thus, currently, doctors have reliable information about the geographic sensitivity of the main AMP. Taking the above mentioned into consideration, we examined efficiency and tolerance of two drugs, that are most com monly used in clinical practice in hospitalized patients with communi ty acquired pneumonia (CAP). The study involved two groups of patients with CAP, who held hospital treatment. The first group used to treat with i/m ceftriaxone 1.0, twice per day, and the second group received 500 mg of levofloxacin orally twice daily. When analyzing the results it was found more clinical efficiency (treatment effect was confirmed by objective clinical and laboratory data and instrumental facts) of the levofloxacin and its tolerance. Taking the above mentioned results and considering levofloxacin is easily handled, this drug should be widely implemented in clinical practice for the treatment of CAPs as a monotherapy and in the case of combination therapy